Ultragenyx Pharmaceutical (RARE) Receivables - Other (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Receivables - Other for 10 consecutive years, with $1.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Other fell 58.33% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (down 58.33% YoY), while the FY2025 annual figure was $1.0 million, down 50.0% from the prior year.
• Receivables - Other held at $1.0 million in Q1 2026 per RARE's latest filing, from $1.0 million in the prior quarter.
• Across five years, Receivables - Other topped out at $12.7 million in Q1 2023 and bottomed at $200000.0 in Q1 2024.
• Historically, Receivables - Other has averaged $2.7 million across 5 years, with a median of $2.1 million in 2025.
• Annual changes were most pronounced in 2024 — Receivables - Other sank 98.43% — and 2025, when it surged 1100.0%.
• Ultragenyx Pharmaceutical's Receivables - Other stood at $6.4 million in 2022, then tumbled by 82.81% to $1.1 million in 2023, then jumped by 81.82% to $2.0 million in 2024, then slumped by 50.0% to $1.0 million in 2025, then changed by 0.0% to $1.0 million in 2026.
• Business Quant data shows RARE's Receivables - Other at $1.0 million in Q1 2026, $1.0 million in Q4 2025, and $2.1 million in Q3 2025.